Mebendazole (R 17635) in enterobiasis. A clinical trial in mental retardates.
The efficacy of mebendazole against enterobiasis was tested on 150 institutionalized mental retardates (range 5-25 years). At the start of the trial all patients swallowed on tablet containing 100 mg mebendazole. Another tablet was administered to all patients 2 weeks and 1, 2 and 3 months later. 19 patients were further treated with one tablet 4 and 5 months after the start of the trial. The presence of E. vermicularis was checked with cellophane adhesive tapes from the anal skin and from the right-hand finger-tips before the trial and after 1, 3 and 6 months. 94 subjects were positive before the trial. At the first post-treatment examination, all patients were found negative. However, 12% were reinfected. No side effects were observed or reported.
D000293:Adolescent; D000328:Adult; D001562:Benzimidazoles / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004757:Enterobius / Q000302:isolation & purification; D005260:Female; D006801:Humans; D008607:Intellectual Disability; D008297:Male; D008463:Mebendazole / Q000627:therapeutic use*; D010123:Oxyuriasis / Q000188:drug therapy* / Q000382:microbiology; D011247:Pregnancy; D012008:Recurrence; D013997:Time Factors
D001562:Benzimidazoles; D008463:Mebendazole